Scholars@Duke
Xiaofei Wang

Xiaofei Wang

Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
xiaofei.wang@duke.edu
Duke Box 2721, Durham, NC 27710
2424 Erwin Road Suite 1102, 11080 Hock Plaza, Duke Box 272, Durham, NC 27705

Scholarly Works - Conferences

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Conference Journal of Clinical Oncology · June 2025 TPS8118Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in ... Full text Cite

Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.

Conference Chin Clin Oncol · October 2023 BACKGROUND AND OBJECTIVE: The application of immunotherapy in cancers, including liver cancer, has been increasing. However, non-proportional hazard (NPH) is often observed in cancer immunotherapy trials. In presence of violation of proportional hazard (PH ... Full text Link to item Cite

Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).

Conference Journal of Clinical Oncology · June 1, 2023 TPS8602 Background: Sarcomatoid mesothelioma is the most aggressive form of pleural mesothelioma and is associated with the worst prognosis of the histologic variants of this disease. In the Checkmate 743 clinical trial the patie ... Full text Cite

A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · June 1, 2023 2569 Background: MEM-288 is a conditionally-replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust dendritic cell-mediated s ... Full text Cite

Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity

Conference Cancer Research · April 14, 2023 AbstractBackground: MEM-288 is a conditionally-replicative oncolytic adenovirus expressing human IFNβ and a recombinant membrane-stable form of CD40L (MEM40). Preclinical studies show MEM-288 induces robust ... Full text Cite

NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Clinical outcomes for limited stage small cell lung cancer (LS-SCLC) remain suboptimal. Standard of care chemoradiation with platinum/etoposide and thoracic radiation to 45 Gy delivered twice daily followed by prophylactic cran ... Full text Cite

Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)We report mature outcomes of LSCLC patients randomized to the 61.2 Gy CB TRT arm of CALGB 30610/RTOG 0538. The study initially included 2 experimental arms, 61.2 Gy CB TRT over 5 weeks and 70 Gy daily (QD) over 7 weeks, both wi ... Full text Cite

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

Conference Journal of Clinical Oncology · May 20, 2021 8505 Background: Although level 1 evidence is lacking, the majority of patients (pts) with LSCLC are treated with a high dose QD TRT regimen in clinical practice. CALGB 30610/RTOG 0538 was designed to determine if administering h ... Full text Cite

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · May 20, 2021 8513 Background: A minority of the approximately 40,000 US patients diagnosed annually with stage III NSCLC can be cured by concurrent CRT. Standard adjuvant immune checkpoint inhibitors (ICI) improve outcome for those patients w ... Full text Cite

Identification of Radiomic Biomarkers for Patients with Locally Advanced Lung Cancer

Conference International Journal of Radiation Oncology*Biology*Physics · September 2019 Full text Cite

Impact of Esophageal Motion on Dosimetry and Toxicity for Lung Radiation Therapy

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Silencing p53 Pathway of Apoptosis Alleviates Ischemia-Reperfusion Injury (IRI) in the Liver

Conference Journal of the American College of Surgeons · October 2017 Full text Cite

Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).

Conference Journal of Clinical Oncology · March 1, 2017 26 Background: Ipilimumab (Ipi) is a humanized CTLA-4 antibody that blocks binding of CTLA-4 to B7, permitting T cell activation through CD28. Phased in Ipi added to chemotherapy (C) may enhance efficacy in NSCLC. Methods: Patien ... Full text Cite

Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)

Conference Cancer Research · October 1, 2014 AbstractBackground: Overexpression of COX-2 has been associated with worse outcome in NSCLC. In C30203, we found that administration of the selective COX-2 inhibitor celecoxib in addition to chemotherapy in ... Full text Cite

Abstract 4707: Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups.

Conference Cancer Research · April 15, 2013 AbstractAims: Performance status (PS) is commonly used for patient stratification in lung cancer clinical trials. Many prognostic models have been proposed to predict survival for non-small-cell lung cancer ... Full text Cite